Cargando…
Corrigendum to “Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19” [Pharmacol. Res. 164 (2021) 105402]
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025071/ https://www.ncbi.nlm.nih.gov/pubmed/33838999 http://dx.doi.org/10.1016/j.phrs.2021.105597 |
| _version_ | 1783675439528542208 |
|---|---|
| author | Di Maria, Emilio Martini, Paolo Gennarelli, Massimo |
| author_facet | Di Maria, Emilio Martini, Paolo Gennarelli, Massimo |
| author_sort | Di Maria, Emilio |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8025071 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-80250712021-04-07 Corrigendum to “Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19” [Pharmacol. Res. 164 (2021) 105402] Di Maria, Emilio Martini, Paolo Gennarelli, Massimo Pharmacol Res Article Elsevier Ltd. 2021-06 2021-04-07 /pmc/articles/PMC8025071/ /pubmed/33838999 http://dx.doi.org/10.1016/j.phrs.2021.105597 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Di Maria, Emilio Martini, Paolo Gennarelli, Massimo Corrigendum to “Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19” [Pharmacol. Res. 164 (2021) 105402] |
| title | Corrigendum to “Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19” [Pharmacol. Res. 164 (2021) 105402] |
| title_full | Corrigendum to “Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19” [Pharmacol. Res. 164 (2021) 105402] |
| title_fullStr | Corrigendum to “Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19” [Pharmacol. Res. 164 (2021) 105402] |
| title_full_unstemmed | Corrigendum to “Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19” [Pharmacol. Res. 164 (2021) 105402] |
| title_short | Corrigendum to “Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19” [Pharmacol. Res. 164 (2021) 105402] |
| title_sort | corrigendum to “naringerin as candidate drug against sars-cov-2: the role for tpc2 genomic variants in covid-19” [pharmacol. res. 164 (2021) 105402] |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025071/ https://www.ncbi.nlm.nih.gov/pubmed/33838999 http://dx.doi.org/10.1016/j.phrs.2021.105597 |
| work_keys_str_mv | AT dimariaemilio corrigendumtonaringerinascandidatedrugagainstsarscov2therolefortpc2genomicvariantsincovid19pharmacolres1642021105402 AT martinipaolo corrigendumtonaringerinascandidatedrugagainstsarscov2therolefortpc2genomicvariantsincovid19pharmacolres1642021105402 AT gennarellimassimo corrigendumtonaringerinascandidatedrugagainstsarscov2therolefortpc2genomicvariantsincovid19pharmacolres1642021105402 |